A $27.5 million senior secured note that amortizes in just 15 months tells you more about VERAXA Biotech’s cash runway than any pipeline slide could. The Zurich-based antibody engineering company closed this debt alongside a $50 million equity line from Lincoln Park Capital as it prepares to list on Nasdaq through its SPAC merger with Voyager Acquisition Corp. — a deal first announced in April 2025 that has been grinding toward a close for over a year. The structure is aggressive: the institutional noteholder can sweep up to 20% of gross proceeds from any future equity raise directly against principal, meaning every capital markets transaction VERAXA executes post-listing immediately feeds debt service.
The deal math deserves scrutiny. VERAXA received roughly $24.1 million in actual cash against $27.5 million in stated principal — a meaningful discount that reflects the risk premium lenders demand from pre-revenue biotechs entering public markets via SPAC. Warrants covering 2.39 million shares at $11.50 pile additional dilution on top of whatever share issuances emerge from the Lincoln Park facility. LPC’s $50 million equity line is nominally VERAXA-controlled, drawn at market price over 24 months, but at-the-market selling into a thinly traded newly listed stock routinely suppresses share price regardless of hedging restrictions. The no-short-selling covenant on LPC is standard boilerplate and offers little structural protection.
What VERAXA is actually buying with this capital stack is the ability to reach clinical proof-of-concept for its BiTAC T-cell engager and ADC programs — both of which are still pre-IND. The technology lineage traces to the European Molecular Biology Laboratory, which provides scientific credibility, but bispecific T-cell engagers are an intensely crowded space dominated by established players with approved products. The company’s differentiation rests entirely on the BiTAC format’s novelty, and nothing in this financing announcement signals that clinical data is imminent.
The single consequence worth tracking: whether VERAXA files an IND for its lead BiTAC program before the 15-month note matures. If clinical entry slips past that window, the company will be forced to refinance or dilute shareholders substantially to retire principal — and at that point the Lincoln Park facility becomes less an equity strategy than a survival mechanism.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
